Grazax grass Allergy Immunotherapy Tablet regulatory update

Merck disclosed in its 4Q12 and 2012 earnings that in January it submitted a BLA to FDA for grass AIT. Merck has exclusive rights to develop and commercialize the tablet-based sublingual allergen immu...